PMID: 16510917Mar 3, 2006Paper

Anthrax in Georgia: epidemiological situation and prognosis

Georgian Medical News
L O MalaniiaLela Bakanidze

Abstract

Anthrax, as an especially dangerous infection, needs permanent control from specialised institutions. The investigations became more important since the attempts to use Bacillus anthracis as the bioterrorism warfare. The issue is more acute for countries where the cases of anthrax are often registered. Cases of anthrax are registered whole around the territory of Georgia (69 regions). Analysis of morbidity during 1980-1989, 1990-1995 and 1996-2004 years showed the trend of increase of frequency of anthrax human cases. The territories where cases of anthrax are registered every year during last 10 years were established. Regions and towns of Georgia were ranged according to the frequency of anthrax cases. Physical -- geographical data and economic characteristics of regions with active hot beds of anthrax are presented. Some of isolates at the National Center for Disease Control and Medical Statistics (NCDC) of Georgia were investigated by molecular -- biological methods. Need for establishing and implementation of complex plan of measures for anthrax prevention is settled.

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Connecticut Medicine
Richard Quintiliani, Richard Quintiliani
Emerging Infectious Diseases
Christina S PolyakEmergency Operations Center International Team
Annals of the New York Academy of Sciences
Márcio A M GalvãoDavid H Walker
© 2021 Meta ULC. All rights reserved